Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM)

Professor of Vaccinology at the University of Oxford, Director of the NIHR Oxford Biomedical Research Centre, Deputy Head, Medical Sciences Division and an Honorary Consultant in Infectious Diseases

Helen McShane is currently Professor of Vaccinology at the University of Oxford, Director of the NIHR Oxford Biomedical Research Centre, Deputy Head, Medical Sciences Division and an Honorary Consultant in Infectious Diseases. Since 2001, Helen has lead a TB vaccine research group at the University of Oxford. She led the development of MVA85A, the first new TB vaccine candidate to enter efficacy testing. Current areas of focus include the development of controlled human mycobacterial challenge models, aerosol delivery of vaccines and immunomonitoring in clinical trials. She collaborates with several research groups across Africa in TB vaccine clinical trials. Most recently, Helen has been leading the coordination of COVID-19 drug trials within Oxford and nationally and is now leading a programme to establish a controlled human infection model with SARS CoV2 which will allow the evaluation of protective immunity.

 Director of The Pirbright Institute

Prof Charleston obtained a BVetMed from the Royal Veterinary College, University of London, UK in 1982. After a period of time in Large Animal Practice, studied for a Masters degree in Molecular Biology at University College London in 1988, then a PhD degree, as a Wellcome Trust Scholar, from the University of London, UK, in 1991. He then carried out postdoctoral research, as a Wellcome Trust Post-doctoral fellow, at the Royal Veterinary College and the Babraham Institute, Cambridge for three years.

He joined The Pirbright Institute (formally known as the Institute for Animal Health) in 1994 and focused on studies of the immune response to viral infections in cattle. In addition, he has provided advice on studies of the immune response to viral infections in cattle. In addition, he has provided advice and expertise on the design of infectious disease challenge models for a wide range of pathogens in important agricultural species.  His research group’s efforts are focused on understanding the immune response to foot-and–mouth disease virus in cattle to develop novel vaccines.

 Head of Finance, The Pirbright Institute

Susan Williams has been Head of Finance at The Pirbright Institute since 2015. Prior to this, she worked in the property management industry for 17 years, 14 of which were in a managerial position. As Finance & IT manager, Susan was a member of the board, part of the Senior Membership Team and made key decisions regarding the strategic direction of the company. Her team produced over 100 service charge audited accounts per year, managed 200 bank accounts and produced consolidated company accounts. They were also heavily involved in running service charge budget and year end meetings for over 85 property estates across the South-East. Susan also played a key role in implementing a new accounting property management system and enabling the smooth relocation of the company on two occasions.

 Executive Director Strategic Planning, Evidence & Engagement, Biotechnology and Biological Sciences Research Council (BBSRC)

Sarah studied for a degree in pharmacology and a PhD in chemoprevention. She has a wealth of experience of the UK research landscape having held senior roles in research council, university, and regional partnership settings. Early in her career she worked at the MRC in research programme management and strategic planning, before moving to Imperial College London. Here her role evolved to Programme Director of Research for both the Faculty of Medicine and partner NHS Trust. She has spent periods of time on secondment to HEFCE (now Research England) to assist with the Research Excellence Framework and with the University of Hong Kong.

Prior to joining BBSRC Sarah was Director of the GW4 Alliance, building strategic, influential relationships with industry, policy makers, funders, and government to deliver collaborative, multidisciplinary projects at scale. As Executive Director at BBSRC, Sarah has responsibility for strategic planning, evidence and evaluation, policy, stakeholder engagement (including oversight of our Strategic Partner Universities and BBSRC strategically supported institute relationships) and the Institutes Assessment Exercise.

Senior Progam Officer, Agricultural Development, Bill & Melinda Gates Foundation

Nick joined the Bill & Melinda Gates Foundation in 2014 as a Senior Program Officer within the Agricultural Development program. Nick is responsible for implementing the foundation’s strategy in animal health, including the development and deployment of products to combat neglected and emerging diseases of livestock, including zoonotic diseases that threaten public health. The foundation’s livestock investments support smallholder livestock keepers in sub-Saharan Africa and South Asia in their efforts to sustainably raise healthy, productive animals. 

Prior to joining the foundation, Nick was a Wellcome Trust Fellow with a focus on veterinary virology and immunology. He has held roles in veterinary practice, academia, vaccine development in industry, and in the UK’s regulatory agency for veterinary drugs and vaccines. Nick holds a degree in veterinary medicine and earned his Ph.D. in immunology at the University of Edinburgh.

Senior Food and Agriculture Adviser in the UK Foreign, Commonwealth and Development Office (FCDO)

Alan is a Senior Food and Agriculture Adviser in the UK Foreign, Commonwealth and Development Office (FCDO), working in FCDO’s Research and Evidence Division. He has worked for the UK Government in agriculture development for over 30 years in Africa and Asia. His background is originally in Fisheries and Aquaculture, and he has PhD in Marine Biology and a Masters in Aquaculture and Fisheries Management. He worked on aquaculture development and inland fisheries management in Bangladesh for 8 years for DFID, including three years working in the Bangladesh Agriculture University. He has also worked with Government of Uganda on agriculture policy reform and for the Malaysian Government.

Managing Director, BioVacc Consulting Ltd, Amersham, UK

During his long career in the pharmaceutical industry with Wellcome Biotechnology, Schering-Plough Animal Health and MSD/Merck Animal Health, Dr Michael James Francis has undertaken global responsibility for a broad range of veterinary and human vaccine projects against viral, bacterial and parasitic diseases. This has led to the development of successful commercial vaccines for all major veterinary livestock and companion animal species, including three animal coronaviruses, utilising both conventional and novel technologies. He is currently the Managing Director of a specialist vaccine development consultancy, BioVacc Consulting Ltd.

Michael was elected as a Fellow of the Royal Society of Biology and awarded an Honorary Associateship of the Royal College of Veterinary Surgeons, in recognition of his contribution to the field of vaccine R&D and animal wellbeing. In addition, he is currently the Chair of the Scientific Strategy Board (SSB) for CVIM at the Pirbright Institute, a Board Member of the International Veterinary Vaccinology Network, a Trustee for the Jenner Vaccine Foundation, an Independent Member of the UK Science Partnership for Animal and Plant Health, a Member of AgResults Brucellosis Vaccine R&D Pilot Judging Panel, a Member of the Zoonoses and a One Health Approach Advisory Group, a member of the BBSRC Veterinary Vaccinology Expert Working Group and a Member of the UK Vaccine Network.

Managing Director, Bellows Consulting Ltd, Berkhamsted, UK

Nicki is an independent consultant. She is the Founder and Director of Bellows Consulting, guiding overarching strategy to translate research from the basic science environment into the clinic and towards the market. She is also an independent Non-Executive Director for the Biotech Growth Trust PLC, a Member of the CARB-X Advisory Board, and a reviewer for Innovate UK.

Previously she was a senior member of the Innovations Division at the Wellcome Trust where she was responsible for the establishment, management and oversight of the Translation Fund, a £30M a year investment. Nicki has previously held positions at AstraZeneca, Global Prior Art, and Brown University.

 Managing Director, BioVacc Consulting Ltd, Amersham, UK

During his long career in the pharmaceutical industry with Wellcome Biotechnology, Schering-Plough Animal Health and MSD/Merck Animal Health, Dr Michael James Francis has undertaken global responsibility for a broad range of veterinary and human vaccine projects against viral, bacterial and parasitic diseases. This has led to the development of successful commercial vaccines for all major veterinary livestock and companion animal species, including three animal coronaviruses, utilising both conventional and novel technologies. He is currently the Managing Director of a specialist vaccine development consultancy, BioVacc Consulting Ltd.

Michael was elected as a Fellow of the Royal Society of Biology and awarded an Honorary Associateship of the Royal College of Veterinary Surgeons, in recognition of his contribution to the field of vaccine R&D and animal wellbeing. In addition, he is currently the Chair of the Scientific Strategy Board (SSB) for CVIM at the Pirbright Institute, a Board Member of the International Veterinary Vaccinology Network, a Trustee for the Jenner Vaccine Foundation, an Independent Member of the UK Science Partnership for Animal and Plant Health, a Member of AgResults Brucellosis Vaccine R&D Pilot Judging Panel, a Member of the Zoonoses and a One Health Approach Advisory Group, a member of the BBSRC Veterinary Vaccinology Expert Working Group and a Member of the UK Vaccine Network.

Professor of Vaccinology at the Nuffield Department of Medicine, University of Oxford, and Deputy Executive Director of the KEMRI-Wellcome Trust Research Programme in Kenya

Professor George Warimwe is Professor of Vaccinology at the Nuffield Department of Medicine, University of Oxford, and Deputy Executive Director of the KEMRI-Wellcome Trust Research Programme in Kenya. His works focuses on viral infections that are transmitted between humans and animals in Africa and vaccine development for their control. While many of these viruses were first discovered in Africa, very little is known regarding their distribution, associated disease burden and their viral genetic diversity in the continent.

Among other projects, Professor’s Warimwe’s research team are at the forefront of addressing the global shortage in Yellow Fever vaccine supply, work which may have a major impact on the number of doses that can be given based on the current global stock of YF vaccine and the number of doses that are produced for future use. His recent work on COVID-19 serology in Kenya has informed decisions on the national pandemic response and remains one of the most comprehensive COVID-19 seroepidemiological programmes in Africa to date.

 Chief Executive Officer at GALVmed

Dr Carolin Schumacher is the Chief Executive Officer at GALVmed since November 2018. GALVmed’s ambition is to make a significant contribution to the economic development of communities in Africa and South Asia, through improvements in livestock production. The CEO leads and develops the activity of GALVmed in line with its mission, vision and accountability. A veterinarian with a Doctorate degree in Veterinary Virology and Post-graduate training in negotiation, finance, leadership, team development, communication and crisis management. Dr Schumacher has 25+ years of experience delivering to market innovative veterinary medicines and solutions that create value for animals, customers, the private sector and society at large. 

Independent Consultant

David qualified as a veterinary surgeon and worked in general veterinary practice before obtaining postgraduate degrees in immunology from the Universities of Birmingham and London.  He then embarked on a research career in exotic viral diseases of livestock culminating as Head of the Pirbright Laboratory when it was part of the Institute for Animal Health. David subsequently moved into the regulatory area, working at the Veterinary Medicines Directorate in the UK before moving to the European Medicines Agency in charge of the Veterinary Medicines Division.  During his career he has published on epizootic diseases of livestock and on regulatory issues, particularly in relation to veterinary vaccines. Since leaving the EMA in 2018, David provides independent advice to governmental and not-for-profit organisations in relation to regulation of veterinary medicines with a particular interest in promoting the availability of vaccines against epizootic diseases of animals.

 Managing Director, PvG Vaccine Bioprocess Consultancy, Sint Anthonis, The Netherlands

Pieter van Gelder has over 35 years of experience in setting up new, high yielding and robust Bioproduction Processes for commercial Vaccines, Scaling Up, Process Transfer into commercial manufacturing and Manufacturing Support (resolving issues). He holds a Master of Science degree in Biology. During his career within the animal health pharmaceutical industry (Intervet International BV, Schering-Plough, MSD-AH) he held positions as Head of Biological Pilot Plant and Director of Bioprocess Technology with global responsibility for establishing over 50 successful commercial vaccine production processes covering a broad range of animal health target species (Pets, Avian, Bovine, Porcine, Fish) applying very diverse types of vaccine technologies (classic live & inactivated, recombinant live vector, baculovirus subunit & VLP, MCA, Rec Protein) and handling very diverse microorganisms (Viruses, Parasites, Intracellular Bacteria, Mycoplasma). As Capital Project Lead he was responsible for several high containment facility construction projects (pilot plant) according to GLP/GMP regulations. He is now since 1.5 years the Managing Director of an independent specialist Vaccine Bioprocess consultancy.

Process Development and Facility Lead, CVIM

Julian Seago is the CVIM Process Development and Facility Lead and responsible for delivery of the science activities within the Centre, across different projects, platforms and disease areas. 

Julian obtained his PhD in Biochemistry from the University of Oxford in 2001, where he used D. melanogaster (a species of fly) as a model organism to study components of the protein complex called the exosome that mediates RNA degradation. After finishing a short post-doctoral position at Oxford working on a transcription factor of C. elegans (a type of threadworm), he continued to characterise exosome proteins in Japan as a Japan Society for Promotion of Sciences (JSPS) Postdoctoral Fellow. Upon returning to the UK, Julian worked on snake disintegrins (venom proteins) at St. Thomas’ Hospital before joining the research team at The Pirbright Institute in 2004. At the Institute his work has focused on three major animal pathogens, classical swine fever virus (CSFV), porcine reproductive and respiratory syndrome virus (PRRSV) and foot-and-mouth disease virus (FMDV). He is particularly interested in the use of reverse genetics to manipulate viral genomes to investigate the virus life cycle and to produce better vaccines. 

 

Process Development and Facility Lead, CVIM

Julian Seago is the CVIM Process Development and Facility Lead and responsible for delivery of the science activities within the Centre, across different projects, platforms and disease areas. 

Julian obtained his PhD in Biochemistry from the University of Oxford in 2001, where he used D. melanogaster (a species of fly) as a model organism to study components of the protein complex called the exosome that mediates RNA degradation. After finishing a short post-doctoral position at Oxford working on a transcription factor of C. elegans (a type of threadworm), he continued to characterise exosome proteins in Japan as a Japan Society for Promotion of Sciences (JSPS) Postdoctoral Fellow. Upon returning to the UK, Julian worked on snake disintegrins (venom proteins) at St. Thomas’ Hospital before joining the research team at The Pirbright Institute in 2004. At the Institute his work has focused on three major animal pathogens, classical swine fever virus (CSFV), porcine reproductive and respiratory syndrome virus (PRRSV) and foot-and-mouth disease virus (FMDV). He is particularly interested in the use of reverse genetics to manipulate viral genomes to investigate the virus life cycle and to produce better vaccines. 

Senior Scientist

Kay Childs graduated with a BSc in Molecular and Cellular Biology from the University of Bath before completing her PhD in Professor Steve Goodbourn’s laboratory at St George’s, University of London in 2001. Her PhD work involved the discovery of two novel proteins that act as co-factors for the transcription factor IRF-2. Kay has more than 20 years research experience studying the molecular biology of RNA viruses and their interactions with the host interferon response. This included the identification of a key cellular receptor for viral RNA that triggers the production of interferon and activation of the host antiviral response. Kay’s work showed that this receptor is targeted by a conserved paramyxovirus protein which blocks its function. Kay joined the Pirbright Institute in 2020 and began working on foot-and-mouth disease virus vaccine development, and the ability of porcine reproductive and respiratory syndrome virus to disrupt the interferon response. Kay joined the CVIM team as Senior Scientist in September 2022.

Senior Scientist

After graduating from the University of Surrey with a BSc in Medical Microbiology, Ben worked in the Quality control, Product Development and Quality assurance departments at Oxoid, a microbial diagnostic GMP subsidiary of Thermo Fisher Scientific. From there, Ben moved on to human vaccine development for the biotechnology company, Emergent BioSolutions, where he was initially involved in the analytical development of Vivotif®, an FDA licensed live attenuated bacterial vaccine against Typhoid fever, before transferring to the virology department to contribute to the analytical and process development of a viral vectored platform. 

Having gained over 10 years GLP industrial experience, Ben successfully obtained a PhD in Molecular Virology from The Pirbright Institute, where his project involved characterisation of a classical swine fever virus (CSFV) protein. Ben then completed several postdoctoral projects, working on a range of viruses that included porcine reproductive and respiratory syndrome virus (PRRSV), foot-and-mouth disease virus (FMDV) and Marek’s disease virus (MDV). This work involved characterising virus virulence and immune evasion, producing recombinant cell lines and identifying suitable viral strains for improved vaccine production, and allowed Ben to contribute to the development and use of reverse genetic platforms and early-stage vaccine invention. 

Ben joined the CVIM team as a Senior Scientist in February 2023. 

Quality Assurance Associate

Daniel has always had a great interest in science and technology, having studied Biology at The University of Kent he proceeded to spend a year in an engineering laboratory in Southern California, working on Near-InfraRed spectrometers performing Quality Control testing and calibration. Returning to the UK, he moved into healthcare diagnostics, gaining experience setting up new laboratories, leading teams of scientists, and maintaining Quality Management System measures to ISO15189. Progressing into a Quality Control role in a microchemistry biotech, he enjoyed conducting quality investigations on Point-of-Care diagnostic medical devices to support continuous improvement in product design, manufacturing, Quality Control methods, and the Quality Management System. As Quality Assurance Associate at Pirbright, he is excited to be involved in the CVIM facility and to have the opportunity to support the needs of the team through development, implementation and maintenance of the CVIM Quality Management System to GLP and GMP regulation – providing effective QA oversight as CVIM’s projects and the facility itself develop and grow. Daniel joined the CVIM team as a Quality Assurance Associate in March 2023.

 Scientist

Yongjie obtained a Master of Science degree from Sichuan Agricultural University, China in 2004, where she carried out a study on agrobacterium mediated gene transformation and particle bombardment transformation in Orchids. She then worked in a company selling HLA genotyping testing kits as a technician before moving to the UK.

Yongjie joined The Pirbright Institute in 2006, where she worked in the Disinfectant Testing group as a Biosafety Assistant to 2012, up to the ISO17025 standard. She then worked as Biosafety adviser in APHA for a year. In 2016, Yongjie returned to The Pirbright Institute, working in the Molecular Virology group for nearly 6 years on several projects aimed at improving foot-and-mouth (FMDV) disease vaccines for East Africa. Yongjie joined the CVIM team as a Scientist in September 2022.

Scientist

Mai graduated with a BSc in Biological Sciences from the University of Reading, where she then obtained her PhD in Virology in Professor Ian Jones’ laboratory. Mai’s PhD involved developing baculovirus expression of virus-like-particles (VLP) in insect cells as a platform for the production of poliovirus vaccines. Following the completion of her PhD in 2019, she continued to work on VLP production but as a next generation vaccine to protect against foot-and-mouth disease (FMD) of livestock. In 2020, Mai began working for contract research organisations (CROs), using her research skills to focus on upstream processes such as protein production in insect cells and antigen quality control. Mai joined the CVIM team as a Scientist in April 2023.